| Ticker: IGYN | 27651 La Paz Road | |
| Exchange: NASDAQ-National Market | Laguna Niguel, California 92677 | |
| Industry: Manufacturing | (714) 362-2500 |
| Type of Shares: | Common Shares | Filing Date: | 4/15/96 | |
| U.S. Shares: | 2,750,000 | Offer Date: | 5/30/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $11.00 - $13.00 | |
| Primary Shares: | 2,750,000 | Offer Price: | $15.00 | |
| Secondary Shares: | 0 | Gross Spread: | $1.05 | |
| Offering Amount: | $33,000,000 | Selling: | $0.63 | |
| Expenses: | $800,000 | Reallowance: | $0.10 | |
| Shares Out After: | 7,494,155 |
| Manager | Tier | Phone |
| Dillon, Read & Co. Inc. | Lead Manager | (212) 906-7000 |
| Montgomery Securities | Co-manager | 4156272220 |
| Auditor: Coopers & Lybrand | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $2.24 | $1.47 | $0.34 | Assets: | $11.37 |
| Net Income: | -$2.65 | -$1.57 | -$1.05 | Liabilities: | $12.90 |
| EPS: | -$0.59 | -$0.29 | -$0.25 | Equity: | -$1.53 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company designs, develops and markets micro-invasive, cost effective devices for diagnosis and treatment of gynecological and reproductive disorders. The company's proprietary technology platform based on micro-optics and micro-access devices provides physicians with the ability to atraumatically access and visualize the abdominal cavity, the uterus and the fallopian tubes. Imagyn's proprietary micro-optics enable physicians to visualize a patient's internal anatomy with the resolution and light efficiency of larger, more invasive devices commonly used today. The company's proprietary, disposable micro-access devices enable physicians to perform procedures outside the hospital without the need for general anesthesia. The company's principal product systems based on these core technologies are the MicroLap microlaparoscopy system, the MicroSpan microhysteroscopy system and the Ovation systems for infertility indications. Compared to traditional procedures, the company's product systems facilitate earlier definitive diagnosis and treatment, significantly lower the procedure cost associated with more invasive surgery and reduce patient discomfort, recovery time and morbidity. |
| Use of Proceeds |
| The proceeds from the offering will be used to fund product introduction, sales and marketing, research and development, capital expenditures and for working capital and other general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.